We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

By LabMedica International staff writers
Posted on 19 Nov 2026

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA). Although highly effective, clozapine carries a risk of neutropenia, a reduction in infection-fighting white blood cells that has traditionally required regular blood monitoring. New findings from Hong Kong suggest that long-term blood-monitoring requirements for patients receiving clozapine may warrant reassessment.

Researchers at the University of Hong Kong (HKUMed) led an international study evaluating long-term blood monitoring requirements for patients receiving clozapine. The research focused on clozapine-associated neutropenia and the burden of mandatory monthly blood tests under Hong Kong’s existing clinical guidelines. Using territory-wide health records, the team investigated whether the frequency of blood monitoring could be adjusted over time based on changes in neutropenia risk.


Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

The population-based study analyzed Hong Kong health records from 2003 to 2019, with follow-up through 2023. Researchers compared 4,868 patients who initiated clozapine treatment with 38,277 receiving other second-generation antipsychotics. The risk of clozapine-associated neutropenia was highest during the first 18 weeks of treatment before progressively declining. After approximately two years, the risk became comparable to that associated with other second-generation antipsychotics, with similar rates of serious neutropenia in both groups.

Based on these findings, researchers suggested maintaining intensive blood monitoring during early treatment, including weekly neutrophil testing for the first 18 weeks and monthly monitoring for up to two years. Beyond this period, monitoring frequency could potentially be reduced to align with practices for other second-generation antipsychotics, subject to formal revisions of Hong Kong’s clinical guidelines. The findings were published in The British Journal of Psychiatry, with contributions from HKUMed, Hong Kong public psychiatric services, and international academic collaborators.

The study forms part of a broader HKUMed research program examining long-term outcomes associated with clozapine treatment. An 18-year population-based study involving 9,456 people with schizophrenia found that continuous clozapine use was associated with lower suicide-related and all-cause mortality compared with continuous treatment using other antipsychotics. Separately, a 20-year self-controlled study of 4,794 patients found that psychiatric hospitalization risk was 79% lower during the first clozapine treatment period and 73% lower during subsequent treatment periods.

Together, these findings highlight the potential benefits of sustained clozapine treatment while supporting further evaluation of long-term monitoring requirements. However, researchers emphasized that the observational findings demonstrate associations rather than causation, and that patients should consult their healthcare providers before making changes to medication or blood-testing schedules.

“For people with TRS, clozapine can be life-changing, but the burden of monthly blood tests while taking the medication can discourage some patients from starting or continuing treatment. Our findings provide an evidence base for a careful, clinically-led review of how long-term monitoring can be made safer, more proportionate and less burdensome,” said Professor Sherry Chan Kit-wa, Department of Psychiatry, School of Clinical Medicine, HKUMed, and corresponding author of the study.

Related Links
HKUMed


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Platelet Function Analyzer
PL-12

Latest Clinical Chem. News

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
18 Nov 2026  |   Clinical Chem.

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
18 Nov 2026  |   Clinical Chem.

FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
18 Nov 2026  |   Clinical Chem.